Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes
Main finding · T2DResult — go to the resultHazard ratio 2.71 95% CI 2.14–3.43Authors' conclusion
MASLD, defined by transaminases or diagnosis code, in pediatric obesity is associated with increased risk for youth-onset type 2 diabetes. MASLD interacts synergistically with intermediate hyperglycemia to dramatically increase the risk. Optimal response in obesity treatment reduces type 2 diabetes risk, despite MASLD.
Study context
- Population
- Children with overweight or obesity in the Swedish Childhood Obesity Treatment Register (BORIS) (1999–2020), linked with national registers10,346 children with overweight/obesity
- Exposure
- Pediatric obesity with MASLD vs obesity alone vs matched controls
- Control individualsn = 59,336
- Outcome
- Youth-onset T2D, ascertained from national registers
Methodological detailsregister-based, matched control individuals
- Register-based
- Matched control individuals
Main finding
T2D · age 30 (cumulative incidence)
Hazard ratio
2.71
95% CI 2.14–3.43
By group
Obesity and MASLDvs Obesity alone
HR 2.71 (95% CI 2.14–3.43)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Joint effect of MASLD and intermediate hyperglycemia on T2D risk
- HR
- 9.04 [6.38-12.79]
Optimal response in obesity treatment and T2D risk
- HR
- 0.23 [0.09-0.57]
Age at T2D diagnosis and follow-up (obesity cohort)
- Median age at T2D diagnosis (Q1, Q3: 14.7, 21.4), years
- 16.9
- Median follow-up (Q1, Q3: 5.1, 11.7), years
- 8.1
Original publication
Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes. Diabetes Care. Published 7 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →